Table 2 Primary analysis 1 – Estimated mean change from pre- to post-RYGB in each biochemical liver function test, non-invasive ICG clearance test, and histological measures

AST, U/L

25

29.9 ± 9.3

23.6 ± 7.9

−6.32 (−15.6, 2.94)

0.03

ALT, U/L

25

31 [26, 38]

20 [17, 34]

−7.56 (−22.0, 6.83)

0.08

ALK, U/L

25

78.2 ± 19.1

84.0 ± 14.9

5.84 (−7.55, 19.2)

0.14

Total bilirubin, mg/dL

25

0.5 [0.4,

0.4 [0.4,

0.01 (−0.15, 0.17)

0.79

Albumin, g/dL

25

4.4 ± 0.3

4.2 ± 0.3

−0.20 (−0.38, −0.02)

<0.001

PT, second

25

11.3 ± 0.6

11.1 ± 0.5

−0.23 (−0.68, 0.23)

0.10

PTT, second

6

29.8 ± 1.6

28.0 ± 0.3

−1.72 (−8.68, 5.25)

0.21

ICG K value

19

0.21 ± 0.04

0.22 ± 0.06

0.01 (−0.04, 0.06)

0.63

NAS steatosis, No. (%)

15

–

0.002

  < 5%

2 (13)

11 (73)

 5–33%

6 (40)

3 (20)

 34–66%

5 (33)

1 (7)

  > 66%

2 (13)

0 (0)

NAS lobular inflammation, No. (%)

15

–

0.04

 No foci

3 (20)

10 (67)

  < 2 foci / 200×

8 (53)

4 (27)

 2–4 foci / 200×

3 (20)

1 (7

  > 4 foci / 200×

1 (7)

0 (0)

NAS Hepatocyte Balloon, No. (%)

15

0.001

 Absent

3 (20)

12 (80)

 Few Balloon Cells

10 (67)

3 (20)

 Many Cells

2 (13)

0 (0)

Fibrosis, No. (%)

15

–

0.005

 None

0 (0)

6 (40)

 Perisinusoidal or periportal

0 (0)

0 (0)

 1A - Mild, zone 3, perisinusoidal

5 (33)

0 (0)

 1B - Moderate, zone 3, perisinusoidal

1 (7)

1 (7)

 1C - Portal/periportal

1 (7)

5 (33)

 2 - Perisinusoidal and portal/periportal

5 (33)

2 (13)

 3 - Bridging fibrosis

3 (20)

1 (7)

 4 - Cirrhosis

0 (0)

0 (0)